Recombinant Anti-IL13 x Anti-IL17 Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-IL13 antibody variable domain is fused to the C terminal of an IgG of anti-IL17 antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Asthma therapy.